Abstract
Objectives
To characterise clinically translatable long-circulating (BR38) and VEGFR2-targeted (BR55) microbubbles (MB) and to assess their ability to discriminate breast cancer models with different aggressiveness.
Methods
The circulation characteristics of BR38 and BR55 were investigated in healthy mice. The relative blood volume (rBV) of MDA-MB-231 (n = 5) or MCF-7 (n = 6) tumours was determined using BR38. In the same tumours in-vivo binding specificity of BR55 was tested and VEGFR2 expression assessed. Data validation included quantitative immunohistological analysis.
Results
BR38 had a longer blood half-life than BR55 (>600 s vs. 218 s). BR38-enhanced ultrasound showed greater vascularisation in MDA-MB-231 tumours (p = 0.022), which was in line with immunohistology (p = 0.033). In-vivo competitive binding experiments proved the specificity of BR55 to VEGFR2 (p = 0.027). Binding of BR55 was significantly higher in MDA-MB-231 than in MCF-7 tumours (p = 0.049), which corresponded with the VEGFR2 levels found histologically (p = 0.015). However, differences became smaller when normalising the levels of BR55 to the rBV.
Conclusions
BR38 and BR55 are well suited to characterising and distinguishing breast cancers with different angiogenesis and aggressiveness. Long-circulating BR38 MB allow extensive 3-dimensional examinations of larger or several organs. BR55 accumulation faithfully reflects the VEGFR2 status in tumours and depicts even small differences in angiogenesis.
Similar content being viewed by others
References
Kaiser WA (2007) Breast magnetic resonance imaging: principles and techniques. Semin Roentgenol 42:228–235
Kiessling F, Huppert J, Palmowski M (2009) Functional and molecular ultrasound imaging: concepts and contrast agents. Curr Med Chem 16:627–642
Berg WA, Blume JD, Cormack JB et al (2008) Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 299:2151–2163
Balleyguier C, Opolon P, Mathieu MC et al (2009) New potential and applications of contrast-enhanced ultrasound of the breast: own investigations and review of the literature. Eur J Radiol 69:14–23
Palmowski M, Huppert J, Hauff P et al (2008) Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res 68:7042–7049
Palmowski M, Lederle W, Gaetjens J et al (2010) Comparison of conventional time-intensity curves vs. maximum intensity over time for post processing of dynamic contrast-enhanced ultrasound. Eur J Radiol 75:149–153
Klibanov AL (2005) Ligand-carrying gas-filled microbubbles: ultrasound contrast agents for targeted molecular imaging. Bioconjug Chem 16:9–17
Lindner JR (2004) Microbubbles in medical imaging: current applications and future directions. Nat Rev Drug Discov 3:527–532
Dayton PA, Rychak JJ (2007) Molecular ultrasound imaging using microbubble contrast agents. Front Biosci 12:5124–5142
Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469–478
Willmann JK, Paulmurugan R, Chen K et al (2008) US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 246:508–518
Willmann JK, Lutz AM, Paulmurugan R (2008) Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 248:936–944
Lyshick A, Fleischer AC, Huamani J et al (2007) Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med 26:1575–1586
Palmowski M, Morgenstern B, Hauff P et al (2008) Pharmacodynamics of streptavidin-coated cyanoacrylate microbubbles designed for molecular ultrasound imaging. Invest Radiol 43:162–169
Palmowski M, Huppert J, Ladewig G et al (2008) Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of anti-angiogenic therapy effects. Mol Cancer Ther 7:101–109
Rychak JJ, Graba J, Cheung AM et al (2007) Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging 6:289–296
Korpanty G, Carbon JG, Grayburn PA et al (2007) Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin Cancer Res 13:323–330
Pochon S, Tardy I, Bussat P et al (2010) BR55: A lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol 45:89–95
Pysz MA, Foygel K, Rosenberg J et al (2010) Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 256:519–527
Naik MU, Naik TU, Suckow AT et al (2008) Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion. Cancer Res 68:2194–2203
Wang C, Navab R, Iakovlev V et al (2007) Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion. Mol Cancer Res 5:1031–1039
Kasper G, Reule M, Tschirschmann M et al (2007) Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway. BMC Cancer 17:7–12
Shrivastava A, von Wronski MA, Sato AK et al (2005) A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng Des Sel 18:417–424
Pillai R, Marinelli ER, Swenson RE (2006) A Flexible Method for preparation of peptide homo- and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups. Biopolymers (Peptide Sci) 84:576–585
Pillai R, Marinelli ER, Fan H (2010) A phospholipid-PEG2000 conjugate of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeting heterodimer peptide for contrast-enhanced ultrasound imaging of angiogenesis. Bioconjug Chem 21:556–562
Watanabe R, Matsumura M, Munemasa T et al (2007) Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol 42:643–651
Morel DR, Schwieger I, Hohn L et al (2000) Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 35:80–85
Lindner JR, Dayton PA, Coggins MP (2000) Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles. Circulation 102:531–538
Ferrara KW, Borden MA, Zhang H (2009) Lipid shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. Acc Chem Res 42:881–892
Wei K, Jayaweera AR, Firoozan S et al (1998) Quantification of myocardial blood flow with ultrasound induced destruction of microbubbles administered as a constant venous infusion. Circulation 97:473–483
Krix M, Kiessling F, Vosseler S et al (2003) Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography. Cancer Res 63:8264–8279
Shimizu H, Miyazaki M, Wakabayashi Y et al (2001) Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 34:683–689
Willmann JK, Cheng Z, Davis C et al (2008) Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 249:212–219
Dadiani M, Kalchenko V, Yosepovich A (2006) Real-time imaging of lymphangiogenic metastasis in orthotopic human breast cancer. Cancer Res 66:8037–8041
Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bzyl, J., Lederle, W., Rix, A. et al. Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38). Eur Radiol 21, 1988–1995 (2011). https://doi.org/10.1007/s00330-011-2138-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-011-2138-y